NCT02524782View on ClinicalTrials.gov

A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

October 7, 2015

Primary Completion Date

April 14, 2017

Study Completion Date

April 14, 2017

Conditions
Type 2 Diabetes
Interventions
BIOLOGICAL

MEDI-4166

MEDI-4166 administered subcutaneously

BIOLOGICAL

Placebo

Placebo administered subcutaneously

Trial Locations (11)

27612

Research Site, Raleigh

27710

Research Site, Durham

32216

Research Site, Jacksonville

33014

Research Site, Miami

33143

Research Site, South Miami

36207

Research Site, Anniston

37920

Research Site, Knoxville

45227

Research Site, Cincinnati

78209

Research Site, San Antonio

78229

Research Site, San Antonio

91911

Research Site, Chula Vista

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY